Genomic Health, Inc.  

(Public, NASDAQ:GHDX)   Watch this stock  
Find more results for GHDX
31.10
+0.70 (2.30%)
After Hours: 31.10 0.00 (0.00%)
Mar 2, 5:07PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.31 - 31.15
52 week 23.90 - 37.74
Open 30.31
Vol / Avg. 139,275.00/111,868.00
Mkt cap 964.03M
P/E     -
Div/yield     -
EPS -0.78
Shares 31.72M
Beta 0.50
Inst. own 96%
May 4, 2015
Q1 2015 Genomic Health Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 10, 2015
Q4 2014 Genomic Health Inc Earnings Call - Webcast
Feb 10, 2015
Q4 2014 Genomic Health Inc Earnings Release
Jan 12, 2015
Genomic Health Inc at JPMorgan Healthcare Conference
Dec 3, 2014
Genomic Health Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -9.07% -8.92%
Operating margin -8.66% -8.57%
EBITD margin - -8.57%
Return on average assets -13.76% -13.55%
Return on average equity -17.39% -16.93%
Employees 684 -
CDP Score - -

Address

301 Penobscot Drive
REDWOOD CITY, CA 94063
United States - Map
+1-650-5569300 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.

Officers and directors

Kimberly J. Popovits Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
G. Bradley Cole Chief Financial Officer, Chief Operating Officer, Principal Financial Officer, Principal Accounting Officer
Age: 58
Bio & Compensation  - Reuters
Steven Shak M.D. Executive Vice President - Research and Development
Age: 63
Bio & Compensation  - Reuters
Julian C. Baker Lead Independent Director
Age: 48
Bio & Compensation  - Reuters
Henry J. Fuchs M.D., Ph.D. Director
Age: 56
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Independent Director
Age: 45
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D., M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Ginger L. Graham Independent Director
Age: 58
Bio & Compensation  - Reuters